Justin Putz
Rheumatology · Bellevue, WANPI 1346864345
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Sobi, Inc at 49.0% of the total. 2025 is the largest year on record at $3,707, more than ten times the $33 reported in 2021.
Across 77 payments — averaging $49.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$2K
- AstraZeneca$312
- Johnson & Johnson$303
- Amgen$278
- UCB, Inc.$232
- AbbVie$197
- plus $607 from 15 others
What the payments were for
- Consulting fees$1,70045%
- Food & beverage$2,02353%
- Education$602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 3 | $1,855 |
| AstraZeneca(2 entities) | 9 | $312 |
| Johnson & Johnson | 10 | $303 |
| Amgen | 13 | $278 |
| UCB, Inc. | 8 | $232 |
| AbbVie | 9 | $197 |
| Novartis | 4 | $114 |
| Radius Health, Inc. | 3 | $86 |
| Organon | 3 | $82 |
| ANI Pharmaceuticals, Inc. | 2 | $57 |
| Tersera Therapeutics LLC | 2 | $50 |
| Sanofi | 2 | $43 |
| GSK | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| CSL Behring | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$132
How this compares
$3,783 in reported general payments places this provider in the 75th percentile of 157 rheumatology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready PenSecukinumab | 12 | $104,466 |
| Enbrel SureclickEtanercept | 11 | $80,891 |
| Humira(Cf) PenAdalimumab | 12 | $79,149 |
| Hydroxychloroquine Sulfate | 25 | $1,489 |
| MethotrexateMethotrexate Sodium | 30 | $1,182 |
| Prednisone | 21 | $224 |
| Alendronate Sodium | 24 | $89 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Bellevue
- Arinola DadaBellevue$69K
- Viviane BuninBellevue$38K
- Kent TaBellevue$22K
- Katherine CristianoBellevue$4K
- Christopher DinhBellevue$2K
- Stanford PengSeattle$3.5M
- Jeff PetersonBothell$2.3M
- Philip MeaseSeattle$2.1M
- Robert EttlingerTacoma$232K
- Richard JimenezBothell$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.